AdiraMedica, a global leader in clinical trial supply services, offers a comprehensive suite of solutions to support the development of innovative, life-changing medicines. Headquartered in the United States and with operations in Canada, Ireland, India, Australia and New Zealand, we offer a full range of clinical trial supply services, including but not limited to clinical drug sourcing, clinical packaging & labeling, distribution and returns management

AdiraMedica was co-founded by Martin Jeiven and Arvind Bhandari in September of 2006. AdiraMedica is strategically located in several countries to support its global clients from 30+ countries. AdiraMedica’s Corporate Office is located in Clark, New Jersey (USA). New Jersey is globally recognized as “The Medicine Chest of the World” and home to more than 300 biotechnology companies and 20 industry-leading pharmaceutical and medical technology companies. AdiraMedica’s state-of-the-art CGMP facility is located in Aston, PA.

At AdiraMedica, we are committed to delivering the highest level of quality and service to our clients. We adhere to the highest standards of regulatory compliance, including Current Good Manufacturing Practices (CGMP), Good Clinical Practices (GCP), Good Distribution Practices (GDP), ICH regulations/guidelines and industry best-practices. Our state-of-the-art facilities, advanced technology and skilled team of professionals enable us to provide efficient, reliable, and cost-effective services to support the success of your clinical trial. 

Our mission is to partner with clients to deliver high-quality, cost-effective, and timely supply services that accelerate the path to groundbreaking therapies. Our core values include integrity, innovation, quality, teamwork, and customer focus. We are committed to building strong and lasting relationships with our clients, based on trust, transparency, and mutual respect.

Thank you for considering AdiraMedica as your partner for global clinical trial supply services. We look forward to working with you to accelerate the development of new and innovative medicines.